Last reviewed 2026-04-22 · How we verify

Lacosamide - rapid titration 1

Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.

Lacosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity. Used for Partial-onset seizures (adjunctive therapy), Primary generalized tonic-clonic seizures (adjunctive therapy).

At a glance

Mechanism of action

Lacosamide is a functionalized amino acid that selectively enhances slow inactivation of voltage-gated sodium channels, which reduces repetitive neuronal firing and prevents seizure propagation. Unlike traditional sodium channel blockers, it does not significantly affect fast inactivation, resulting in a favorable safety profile. This mechanism makes it effective as an adjunctive antiepileptic agent.

Approved indications

• Partial-onset seizures (adjunctive therapy)
• Primary generalized tonic-clonic seizures (adjunctive therapy)

Common side effects

• Dizziness
• Headache
• Nausea
• Diplopia
• Ataxia
• Vomiting
• Tremor

Key clinical trials

• A Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Diabetic Neuropathy (PHASE3)
• Efficacy and Safety of Rapid Titration Protocols of Lacosamide (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Lacosamide - rapid titration 1 CI brief — competitive landscape report
• Lacosamide - rapid titration 1 updates RSS · CI watch RSS
• Seoul National University Hospital portfolio CI